congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Oral
Edoxaban
AHA 2023 | November 10-13, 2023
Clinical outcomes in TAVR patients receiving oral anticoagulation according to renal function: A prespecified analysis of the ENVISAGE-TAVI AF trial
Mini-Oral
Edoxaban
AHA 2023 | November 10-13, 2023
The duration of anticoagulant treatment and its association with HRQoL and treatment satisfaction in patients with AF after TAVR: Results from ENVISAGE-TAVI AF